Summary
In order to evaluate the efficacy of two different sequences of second and third line hormonotherapy in advanced post-menopausal breast cancer, 257 women aged 36–91 years (mean age: 63.6 years) who had become resistant to tamoxifen (TAM), entered into a multicenter randomized trial comparing two different regimens: 1) Aminoglutethimide (Ag) 500 mg/day with hydrocortisone supplementation from 30 to 60 mg/day; and 2) oral medroxyprogesterone acetate (MPA) 500 mg twice a day.
250 patients were evaluated following second line hormone therapy and, after cross-over, 128 following third line hormonotherapy.
No significant difference was observed, during either second or third line therapies, for toxicity, survival, or response rate; however, in both second and third line therapies the median time to progression was significantly longer with Ag therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Elomaa I, Blomqvist C, Rissanen P: Aminoglutethimide as second line therapy in advanced breast cancer. Breast Cancer Res Treat 7 (suppl): 51–54, 1986
Canney PA, Priestman TJ, Griffiths T, Latief TN, Mould JJ, Spooner D: Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. J Natl Cancer Inst 80: 1147–1151, 1988
Garcia-Giralt E, Hurteloup P, Chollet P, Bastit P, Chevalier B, Delozier T, Le Floch O, Mercier M, Monicuquet P, Metz R, Delgado M, Weber B, Serin D, Daban A, Pourny C, Olivier JP, Roche H, Van V, Pouillart P: Breast cancer first line hormonotherapy: a multicenter randomized trial comparing TAM with MAP and their sequential administration. Proc ASCO 1987, p 61
Congdon J, Green S, O'Sullivan J, Hynes H, Belt R, Gail K, Zidar B, Osborne CK, for the Southwest Oncology Group: Megesterol acetate (MA) and aminoglutethimide/hydrocortisone (AG) in sequence or in combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer. Proc ASCO 10: 43, 1991
Nemoto T, Rosner D, Patel JK, Dao TL: Aminogluthethimide in patients with metastatic breast cancer. Cancer 63: 1673–1675, 1989
Alberto P, Mermillod B, Kaplan E: A clinical trial of aminoglutheimide in advanced breast carcinoma: low response in patients previously treated with medroxyprogesterone. Eur J Cancer Clin Oncol 21: 423–428, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garcia-Giralt, E., Ayme, Y., Carton, M. et al. Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Tr 24, 139–145 (1992). https://doi.org/10.1007/BF01961246
Issue Date:
DOI: https://doi.org/10.1007/BF01961246